Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

NCT02260037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Epinastine nasal
DRUG: Placebo

Sponsor

Boehringer Ingelheim